Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Return on Sales (2019 - 2025)

Bioadaptives' Return on Sales history spans 7 years, with the latest figure at 78.96% for Q4 2025.

  • Quarterly results put Return on Sales at 78.96% for Q4 2025, down 2742.0% from a year ago — trailing twelve months through Dec 2025 was 88.61% (down 3706.0% YoY), and the annual figure for FY2025 was 85.23%, down 1426.0%.
  • Return on Sales for Q4 2025 was 78.96% at Bioadaptives, up from 81.93% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 2.65% in Q4 2023 to a low of 1261.11% in Q1 2025.
  • The 5-year median for Return on Sales is 50.79% (2022), against an average of 114.97%.
  • Peak annual rise in Return on Sales hit 22208bps in 2025, while the deepest fall reached -125606bps in 2025.
  • Year by year, Return on Sales stood at 23.27% in 2021, then tumbled by -200bps to 69.91% in 2022, then surged by 104bps to 2.65% in 2023, then plummeted by -2044bps to 51.55% in 2024, then plummeted by -53bps to 78.96% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 78.96%, 81.93%, and 49.06% for Q4 2025, Q3 2025, and Q2 2025 respectively.